ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with a 20% YoY revenue increase and improved gross margin. Despite a net loss, the reduction from the previous year shows progress. Positive cash flow and increased operating expenses suggest strategic investments. However, risks such as regulatory and supply chain challenges were noted, but no major negative sentiment was evident in the Q&A section. Given the company's market cap and the financial improvements, a positive stock price movement of 2% to 8% is likely over the next two weeks.
Key Financial Performance
Revenue ADMA Biologics reported revenue of $60 million for Q1 2026, representing a 20% increase year-over-year. The growth was attributed to higher demand for the company's plasma-derived products and expanded distribution channels.
Gross Margin The gross margin improved to 50% in Q1 2026, up from 45% in Q1 2025. This 5% increase was driven by operational efficiencies and cost-saving initiatives implemented during the year.
Net Loss The company reported a net loss of $5 million for Q1 2026, compared to a net loss of $8 million in Q1 2025. This improvement was due to increased revenue and better cost management.
Operating Expenses Operating expenses were $25 million in Q1 2026, up from $22 million in Q1 2025, reflecting a 13.6% increase. The rise was primarily due to investments in research and development and marketing efforts.
Cash Flow Cash flow from operations was positive at $10 million in Q1 2026, compared to $7 million in Q1 2025, marking a 42.9% increase. This improvement was driven by higher revenue and improved working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company may face challenges related to regulatory approvals for new products or changes in existing product lines, which could impact their ability to bring products to market in a timely manner.
Supply Chain Disruptions: Potential disruptions in the supply chain could affect the company's ability to manufacture and distribute products efficiently, leading to delays and increased costs.
Economic Uncertainties: Economic fluctuations could impact the company's financial performance, affecting consumer demand and operational costs.
Strategic Execution Risks: Challenges in executing strategic initiatives could hinder the company's growth and expansion plans, affecting overall business performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Corporate Progress: Adam Grossman will provide an update on corporate progress.
Financial Results Overview: Terry Kohler will provide an overview of the company's first quarter 2026 financial results.
Summary Remarks: Adam Grossman will provide some brief summary remarks before opening the call up for questions.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adam Grossman
Biologics Financial
CEO Director
CFO Treasurer
Canaccord Genuity
Cantor Fitzgerald
Co Founder
Co Research
Corp Research
Director Terence
Division Gary
Division Kristen
Division PM
EDT afternoon
Fitzgerald Co
Gary Nachman
Genuity Corp
Instructions answer
Kluska Cantor
Kohler CFO
Kristen Kluska
Nachman Canaccord
PM EDT
Petrone Mizuho
Research Division
Terence Kohler
Treasurer Petrone
answer session
end comment
session request
ADMA Transcript
ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary indicates strong financial performance with a 20% YoY revenue increase and improved gross margin. Despite a net loss, the reduction from the previous year shows progress. Positive cash flow and increased operating expenses suggest strategic investments. However, risks such as regulatory and supply chain challenges were noted, but no major negative sentiment was evident in the Q&A section. Given the company's market cap and the financial improvements, a positive stock price movement of 2% to 8% is likely over the next two weeks.
ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary reveals strong financial performance with record high revenue and margins, optimistic guidance, and effective strategies for ASCENIV's growth. The Q&A section indicates positive analyst sentiment and successful third-party supply contracts. Despite some risks and uncertainties, the company's robust financial health, strategic partnerships, and growth prospects outweigh potential negatives, suggesting a positive stock price movement.
ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
ADMA Biologics, Inc. (ADMA) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call summary presents strong financial metrics, including a 10% QoQ revenue increase and significant gross margin expansion. The Q&A reveals optimism about ASCENIV's market potential and raised 2026 guidance, despite some management ambiguity. No negative trends were identified. Given the market cap, a positive stock price movement (2% to 8%) is anticipated due to strong financial performance, optimistic guidance, and strategic growth initiatives.
ADMA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
